...
首页> 外文期刊>Bioorganic and Medicinal Chemistry Letters >Carbonic anhydrase inhibitors. Inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, IX, and XII with Schiff's bases incorporating chromone and aromatic sulfonamide moieties, and their zinc complexes.
【24h】

Carbonic anhydrase inhibitors. Inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, IX, and XII with Schiff's bases incorporating chromone and aromatic sulfonamide moieties, and their zinc complexes.

机译:碳酸酐酶抑制剂。用结合了色酮和芳族磺酰胺基团的席夫碱及其锌络合物抑制胞质/肿瘤相关的碳酸酐酶同工酶I,II,IX和XII。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

A series of Schiff's bases was prepared by reaction of 3-formyl-chromone or 6-methyl-3-formyl-chromone with aromatic sulfonamides, such as sulfanilamide, homosulfanilamide, 4-aminoethyl-benzenesulfonamide, a pyrimidinyl-substituted sulfanilamide derivative, sulfaguanidine and 4-amino-6-trifluoromethyl-benzene-1,3-disulfonamide. The zinc complexes of these sulfonamides have also been obtained. The new derivatives and their Zn(II) complexes were investigated for the inhibition of four physiologically relevant isozymes of carbonic anhydrase (CA, EC 4.2.1.1): the cytosolic isoforms I and II, as well as the tumor-associated, transmembrane isozymes CA IX and XII. Except for the sulfaguanidine-derived compounds which were devoid of activity against all isozymes, the other sulfonamides and their metal complexes showed interesting inhibitory activity. Against isozyme CA I, the inhibition constants were in the range of 13-100 nM, against isozyme CA II in the range of 1.9-102 nM, against isozyme CA IX in the range of 6.3-48nM, and against CA XII in the range of 5.9-50nM. Generally, the formyl-chromone derived compounds were better CA inhibitors as compared to the corresponding 6-methyl-chromone derivatives, and for the simple, benzenesulfonamide derivatives activity increased with an increase of the spacer from sulfanilamide to homosulfanilamide and 4-aminoethylbenzenesulfonamide derivatives, respectively. Some of these compounds may show applications for the development of therapies targeting hypoxic tumors in which CA IX and XII are often highly overexpressed.
机译:通过使3-甲酰基-色酮或6-甲基-3-甲酰基-色酮与芳族磺酰胺如磺胺,高磺胺,4-氨基乙基-苯磺酰胺,嘧啶基取代的磺酰胺衍生物,磺胺胍和4-氨基-6-三氟甲基-苯-1,3-二磺酰胺。还已经获得了这些磺酰胺的锌络合物。研究了新的衍生物及其Zn(II)配合物对四种生理相关的碳酸酐酶同功酶(CA,EC 4.2.1.1)的抑制作用:胞质同工型I和II,以及与肿瘤相关的跨膜同工酶CA IX和XII。除了对所有同工酶均无活性的磺胺胍衍生化合物外,其他磺酰胺类及其金属配合物均表现出令人感兴趣的抑制活性。对于同工酶CA I,抑制常数在13-100 nM的范围内,对同工酶CA II在1.9-102 nM的范围内,对同工酶CA IX在6.3-48nM的范围内,以及对CA XII的抑制常数在5.9-50nM。通常,与相应的6-甲基色酮衍生物相比,从甲酰基色酮衍生的化合物是更好的CA抑制剂,并且简单地,苯磺酰胺衍生物的活性随磺酰胺至高磺酰胺和4-氨基乙基苯磺酰胺衍生物间隔基的增加而增加。 。这些化合物中的某些可能显示出开发针对低氧肿瘤的疗法的应用,其中CA IX和XII通常高度过表达。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号